Stockscreener 앱 받기
3.74
1.58%
-0.06
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Bull Run: Is Relmada Therapeutics Inc in accumulation or distribution phase2025 Growth vs Value & Detailed Earnings Play Strategies - baoquankhu1.vn
Relmada’s New Phase 3 Bladder Cancer Trial Adds a Fresh Catalyst to Its Pipeline - TipRanks
FDA endorses Relmada’s registrational strategy for bladder cancer therapy - Indian Pharma Post
Is Relmada Therapeutics Inc stock affected by interest rate hikesWeekly Trend Summary & High Win Rate Trade Tips - Bộ Nội Vụ
Relmada’s BOOST phase 3 bladder cancer trial sets up a new catalyst for RLMD investors - MSN
Relmada receives FDA feedback for bladder cancer therapy trials By Investing.com - Investing.com Nigeria
Will Relmada Therapeutics Inc. (4E2) stock outperform energy sector in 2025Footwear buying guidance for all day wear during busy schedules focuses on foot fatigue reduction, making it helpful for judging overall value. - Улправда
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - Investing News Network
Relmada Therapeutics (RLMD) Advances NDV-01 with FDA Guidance - GuruFocus
Relmada gets FDA alignment on NDV-01 bladder cancer trial designs - StreetInsider
FDA backs new bladder cancer studies for patients with few options left - Stock Titan
Will Relmada Therapeutics Inc. stock benefit from infrastructure spendingForecast Cut & Low Risk High Reward Ideas - Улправда
How supply chain issues affect Relmada Therapeutics Inc. stockBuy Signal & Weekly Momentum Stock Picks - Улправда
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Corient Private Wealth LLC Invests $120,000 in Relmada Therapeutics, Inc. $RLMD - Defense World
Small Cap Biotech In 2025: Winning Pivots And Zombie Killers - Citeline News & Insights
Relmada’s BOOST Phase 3 Bladder Cancer Trial Sets Up a New Catalyst for RLMD Investors - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update - Defense World
Jefferies Financial Group Begins Coverage on Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of Relmada Therapeutics (RLMD) with Buy Recommendation - Nasdaq
Relmada Therapeutics (RLMD) Initiates Coverage with Buy Rating | RLMD Stock News - GuruFocus
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Treasury Yields: Is NEHC stock recession proof2025 Trading Recap & Weekly Stock Breakout Alerts - moha.gov.vn
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot - Investing.com Nigeria
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot By Investing.com - Investing.com South Africa
Jefferies Starts Relmada Therapeutics Inc (RLMD) at Buy - StreetInsider
Inflation Data: Will Las Vegas Sands Corp stock outperform value peersPortfolio Return Summary & Real-Time Market Sentiment Reports - moha.gov.vn
Is Relmada Therapeutics Inc. stock supported by strong cash flowsPortfolio Growth Summary & Entry Point Confirmation Alerts - Улправда
Why Relmada Therapeutics Inc. stock remains undervalued2025 Buyback Activity & Real-Time Buy Zone Alerts - Улправда
Momentum Shift: Why Relmada Therapeutics Inc. (4E2) stock benefits from AI revolution2025 Performance Recap & Low Risk Growth Stock Ideas - Улправда
Recap Report: Is Relmada Therapeutics Inc. stock supported by strong cash flowsBond Market & AI Enhanced Trading Alerts - Улправда
How Relmada Therapeutics Inc. (4E2) stock moves in volatile trading sessions2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
Is Relmada Therapeutics Inc. stock supported by innovation pipeline2025 Market Trends & Reliable Intraday Trade Alerts - Улправда
Have you been able to find a good deal on Relmada Therapeutics Inc’s shares? - uspostnews.com
RelmadaA New Contender To Watch In Bladder Cancer Drug Development? - RTTNews
Maged Shenouda Increases Stake in Relmada Therapeutics Inc (RLMD) - GuruFocus
Relmada Therapeutics (NASDAQ:RLMD) CFO Buys $48,059.80 in Stock - MarketBeat
Relmada Therapeutics updates executive contracts and increases salaries By Investing.com - Investing.com Australia
Relmada Therapeutics Amends Executive Employment Agreements - TipRanks
Relmada Therapeutics updates executive contracts and increases salaries - Investing.com
What analysts say about Relmada Therapeutics Inc stockMarket Insider Reports & Exceptional Profit Growth Tips - earlytimes.in
Aug Drivers: Can Relmada Therapeutics Inc stock outperform in 2025 bull marketAnalyst Upgrade & Safe Entry Trade Reports - moha.gov.vn
Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Taking on analysts’ expectations and winning: Relmada Therapeutics Inc (RLMD) - setenews.com
Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20 - Nasdaq
Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser
Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser
4.73%
0.92%
자본화:
|
볼륨(24시간):